Related Experiment Video
Updated: Sep 24, 2025
A Novel in vivo Gene Transfer Technique and in vitro Cell Based Assays for the Study of Bone Loss in Musculoskeletal Disorders
Published on: June 8, 2014
Identification and Characterization of a Novel Long Noncoding RNA that Regulates Osteogenesis in Diet-Induced Obesity
Zhekai Hu1, Wei Qiu1, Yuedi Yu1
1Division of Oral Biology, Tufts University School of Dental Medicine, Boston, MA, United States.
Abstract:
As a precursor to type 2 diabetes mellitus (T2D), obesity adversely alters bone cell functions, causing decreased bone quality. Currently, the mechanisms leading to alterations in bone quality in obesity and subsequently T2D are largely unclear. Emerging evidence suggests that long noncoding RNAs (lncRNAs) participate in a vast repertoire of biological processes and play essential roles in gene expression and posttranscriptional processes. Mechanistically, the expression of lncRNAs is implicated in pathogenesis surrounding the aggregation or alleviation of human diseases. To investigate the functional link between specific lncRNA and obesity-associated poor bone quality and elucidate the molecular mechanisms underlying the interaction between the two, we first assessed the structure of the bones in a diet-induced obese (DIO) mouse model. We found that bone microarchitecture markedly deteriorated in the DIO mice, mainly because of aberrant remodeling in the bone structure. The results of in vitro mechanistic experiments supported these observations. We then screened mRNAs and lncRNAs from DIO bones and functionally identified a specific lncRNA, Gm15222. Further analyses demonstrated that Gm15222 promotes osteogenesis and inhibits the expression of adipogenesis-related genes in DIO via recruitment of lysine demethylases KDM6B and KDM4B, respectively. Through this epigenetic pathway, Gm15222 modulates histone methylation of osteogenic genes. In addition, Gm15222 showed a positive correlation with the expression of a neighboring gene, BMP4. Together, the results of this study identified and provided initial characterization of Gm15222 as a critical epigenetic modifier that regulates osteogenesis and has potential roles in targeting the pathophysiology of bone disease in obesity and potential T2D.
Insights
Obesity impairs bone quality by altering bone remodeling. A specific long noncoding RNA, Gm15222, was identified to promote bone formation and inhibit fat cell development via epigenetic mechanisms, offering potential therapeutic targets for obesity-related bone disease.
Area of Science:
- Molecular Biology
- Endocrinology
- Bone Biology
Background:
- Obesity is a precursor to type 2 diabetes mellitus (T2D) and negatively impacts bone quality.
- The precise molecular mechanisms linking obesity to diminished bone quality remain largely unknown.
- Long noncoding RNAs (lncRNAs) are emerging as key regulators in various biological processes and disease pathogenesis.
Purpose of the Study:
- To investigate the functional role of a specific lncRNA in obesity-associated bone quality decline.
- To elucidate the molecular mechanisms by which lncRNAs influence bone health in obesity.
- To identify potential therapeutic targets for bone diseases linked to obesity and T2D.
Main Methods:
- Utilized a diet-induced obese (DIO) mouse model to assess bone structure and microarchitecture.
- Performed in vitro mechanistic experiments to validate observations.
- Screened for differentially expressed mRNAs and lncRNAs in DIO mouse bones.
- Identified and functionally characterized the lncRNA Gm15222.
Main Results:
- DIO mice exhibited significant deterioration in bone microarchitecture due to aberrant remodeling.
- Gm15222 was identified as a key lncRNA regulating bone quality in DIO.
- Gm15222 promotes osteogenesis and inhibits adipogenesis by recruiting KDM6B and KDM4B, modulating histone methylation of osteogenic genes.
- Gm15222 showed a positive correlation with the expression of the neighboring gene BMP4.
Conclusions:
- Gm15222 acts as a critical epigenetic modifier regulating osteogenesis in the context of obesity.
- This study provides initial characterization of Gm15222's role in bone pathophysiology.
- Gm15222 presents a potential therapeutic target for managing bone disease associated with obesity and T2D.
